论文部分内容阅读
目的 :探讨环胞霉素 A(Cs A)联合他莫昔芬 (TAM)逆转非霍奇金淋巴瘤 (NHL )多药耐药的临床疗效。方法 :采用免疫组织化学标记链亲和素生物素法检测 NHL的 P-糖蛋白表达。将 P-糖蛋白表达阳性者分层随机分为两组 ,比较 Cs A联合 TAM加化疗组与单用化疗组的疗效。结果 :P-糖蛋白的阳性表达率在初治 NHL 为 9.6 % ,在复发难治 NHL 为 79.2 % (P<0 .0 0 1)。Cs A联合 TAM对逆转 NHL 的多药耐药有一定作用 ,加逆转剂组的化疗疗效高于不加逆转剂组 (P<0 .0 5 )。结论 :Cs A联合 TAM逆转 NHL 的多药耐药是安全和具有一定疗效的。
Objective: To investigate the clinical efficacy of cyclosporin A (Cs A) combined with tamoxifen (TAM) in reversing multidrug resistance in non-Hodgkin’s lymphoma (NHL). Methods: The expression of P-glycoprotein in NHL was detected by immunohistochemical streptavidin biotin method. Patients with positive expression of P-glycoprotein were randomly divided into two groups. The curative effect of CsA combined with TAM plus chemotherapy group and chemotherapy alone group was compared. Results: The positive expression rate of P-glycoprotein was 9.6% in the naive group and 79.2% in the refractory relapsed NHL group (P <0.01). CsA combined with TAM could reverse the multidrug resistance of NHL, and the effect of chemotherapy with reversal agent was higher than that without reversal agent (P <0.05). Conclusion: CsA combined with TAM reverses NHL multidrug resistance is safe and has a certain effect.